Dexamethasone Single Dose and Risk of Postoperative Nausea and Vomiting in Tonsillectomy Patients

Dr. Asif Mahajan¹, Dr. Arshid Ali², Dr Aneesa Afzal³

1, 2, 3 Senior Resident, SKIMS Medical College and Hospital Srinagar, J&K India

Abstract: <u>Introduction</u>: Several meta-analyses investigating morbidity following tonsillectomy have demonstrated that under controlled conditions a single intravenous dose of Dexamethasone (DX) is an effective, safe and inexpensive method of reducing the incidence of postoperative nausea and vomiting (PONV) following tonsillectomy in children¹⁻⁵. Unfortunately, there is substantial variability across these studies with respect to design, surgical technique, method of acquiring hemostasis and age of patients. We undertook the study to find out the effectiveness of a single IV dose of dexamethasone (0.15 mg/kg) on postoperative nausea and Vomiting (PONV) intonsillectomy patients. <u>Methods</u>: This study was conducted with 100 patients who underwent tonsillectomy. Patients were divided into two groups of 50, where one group A(n=50) received preoperative dexamethasone and the other group B (n=50) were not given injection Dexamethasone Postoperative nausea and vomiting (PONV) episodes of both groups were recorded in first 6 hours, then next 6-24 hours and of 24 hours. Inj. metoclopromide0.15 mg/kg was administered as rescue antiemetic, ifmore than two episodes of vomiting in an hour or nausea lasting for more than half hour occurred. If PONV still persisted, inj. ondansetron0.1 mg/kg was administered as rescue antiemetic. <u>Results</u>: There is significant decreased in the incidence of PONV in first 6 hours and also after 24 hours. <u>Conclusions</u>: A single dose of preoperative intravenous dexamethasone significantly decreased the postoperative nausea and vomiting in tonsillectomy patients.

Keywords: Tonsillitis, Tonsillectomy, Pain relief, Dexamethasone, PONV- postoperative nausea and vomiting

1. Introduction

Several meta-analyses investigating morbidity following tonsillectomy have demonstrated that under controlled conditions a single intravenous dose of Dexamethasone (DX) is an effective, safe and inexpensive method of reducing the incidence of postoperative nausea and vomiting children¹⁻⁵. (PONV) following tonsillectomy in Unfortunately, there is substantial variability across these studies with respect to design, surgical technique, method of acquiring hemostasis and age of patients.Oropharyngeal pain and irritation of gastric mucosa byswallowed blood are two main contributors towards high incidence of PONV following tonsillectomy.

Steroids can have beneficial effects on post-tonsillectomy morbidity due to their anti-inflammatory and antiemetic properties.We undertook the study to find out the effectiveness of a single IV dose of dexamethasone (0.15 mg/kg) on postoperative nausea and Vomiting (PONV).

2. Materials and Methods

This was a prospective study conducted in Department of ENT and HNS of SKIMS Medical College and Hospital, Srinagar tertiary care hospital between January.2018 to March 2019. 100 patients were enrolled in this study and were randomly divided into two equal groupsA and B of 50 patients each. The patients were explained about the study and the procedure involved and written and informed consent was taken. Ethical clearance for the study was obtained from the hospital ethical committee. Relevant clinical and demographic data were obtained from the concerned patient. They also underwent detailed ENT examination.

Patients with coagulopathy, diabetes, gastritis, peptic ulcer, hypertension and cardiovascular or renal disease or on therapy with corticosteroids, anti-histaminic, or aspirin were excluded. Preoperatively tonsil size was graded into four grades:

- I Tonsil within tonsillar fold
- $\mathrm{II}-\mathrm{Just}$ outside the tonsillar fold
- III Well outside the tonsillar fold
- IV Reaching uvula or past uvula

Patients in group A (n=50) were administered intravenous dexamethasone (0.15 mg/kg) after the induction of anaesthesia. Group B patients (n=50) were not administered injection dexamethasone.

Episodes of postoperative Nausea and vomiting (PONV) in both groups i.e. Group A and Group B were recorded in first 6 hours, than next 6-24 hours and after 24 hours.Total number of episodes of vomiting for each patient were noted. Rescue antiemetic Inj. Metaclopromide 0.15mg/kg was given if more than two episodes of vomiting occurred in one hour or nausea lasting more than half hour occurred. If PONV still persisted, Inj. Ondansterone 0.1 mg/kg was given as rescue antiemetic.

3. Results

Each group comprised of 50 patients. Except for the age, all demographic characteristics including type of surgery and tonsil size were comparable for both groups (Table 1). Age was slightly higher in the cases groupi.e9.58 \pm 4.02 as

compared to control group 6.86 ± 3.3 .(Table.1) The mean weight of cases group A was 23.86 ± 9.3 kg, as compared to control group B 30.75 ± 12.45 kg. (Table .1)

Table 1			
Demographic Data			
Parameter	Control	Dexamethasone	
Age	6.86 <u>+</u> 3.3	9.58 <u>+</u> 4.02	
Weight (kg)	30.75 <u>+</u> 12.45	23.86 <u>+</u> 9.3	
M/F (no of pts)	20/30	22/28	
Surgery type (No of pts $T/T + A$	22/28	23/27	
Tonsil size (No pts) I/II/II/IV	4/15/16/15	3/16/17/14	

Age and weight are presented as mean \pm standard deviation T – tonsillectomy; T+ A – tonsillectomy and adenoidectomy Incidence of nausea, vomiting and requirement of anti-emetic were significantly different for two groups.

Table 2			
Postoperative nausea Vomiting (PONV)			
Parameter	Control	Dexamethasone	
Nausea			
0-6 hours	16 (32%)	5(10%)	
6- 24 hours	9 (18%)		
Vomiting			
0-6 hours	15 (30%)	3(6%)	
6- 24 hours	9 (18%)	1(2%)	
0-24 hours	8(16%)	1(2%)	
Patients with multiple episodes of vomiting	8 (16%)	2(4%)	
Total number of episodes of vomiting	28	13	
Rescue analgesic			
0-6 hours	7(14%)	1(2%)	
6- 24 hours	4(8%)	1(2%)	

Data indicated as number of patients (% of patients)

Incidence of nausea in first 6 hours was significantly low in dexamethasone group (10%) compared to control group (32%). Similarly incidence of nausea in next 6- 24 hours was negligible in dexamethasone group (0%) compared to control group (28%). (Table. 2)

Incidence of Vomiting in first 6 hours was significantly low in dexamethasone group (6%) compared to control group (30%).Similarly incidence of vomiting in next 6- 24 hours was significantly low in dexamethasone group (2%) compared to control group (18%). After 24 hours same trend was present. (Table. 2)

Eight patients in control versus two in dexamethasone group had two or more episodes of vomiting (Table 2). Total number of vomiting episodes were significantly higher in control (28) compared to dexamethasone (13) group. (table.2)

The requirement of rescue antiemetic was significantly lowin dexamethasone group (2%) compared to control group (14%) in first 6 hours and same trend was seen in next 6-24 hours. (Table 2)

4. Discussion

complications Common of tonsillectomy are postoperativenausea and vomiting (PONV), pain, and bleeding.⁶Nonsteroidal anti-inflammatory drugs (NSAIDs) have been widely used in this setting for their pronounced analgesic efficacy and a lack of the emetogenic effect inherent to opioids. However, classic NSAIDs, through reversible platelet inhibition, further increase the risk of after tonsillectomy.^{7,8} Dexamethasone has bleeding antiemetic properties in the surgical setting.⁹An international expert panel recommended dexamethasone, alone or as part of a multimodal regimen, forPONV prophylaxis in adults and children.¹⁰ It has been suggested that, especially in children undergoing tonsillectomy, dexamethasone is useful, not only for its antiemetic but also for its analgesic effects, and that it should be used routinely because the adverse effects and cost appear negligible.^{11,12,13,14}Indeed, dexamethasone for tonsillectomy has become standard care in many institutions.¹⁵The dose response of dexamethasone for prevention of PONV symptoms in pediatric tonsillectomy remains unclear, although doses up to 1 mg/kg have been tested. 16,17,18,19

The 2008 guidelines of the Associationof Paediatric Anaesthetists of Great Britain and Ireland conclude that in patients undergoing tonsillectomy, "dexamethasone 0.15 mg/kg provided good reduction in postoperative vomiting with no adverse effects."²⁰In our study, we also administered 0.15mg/kg of I/V Dexamethasone to our patients. Expert panels have recommended the widespread use of patients.¹⁰Prophylactic dexamethasone in surgical dexamethasone has become standard care in children undergoing tonsillectomy in many institutions.^{11,12,13} Several authorshave suggested that dexamethasoneshould be given in considerably higher doses than what we tested.^{16,17,18,19}Our trial showed that dexamethasone significantly decreased the incidence of PONV in children undergoing tonsillectomy.

Karamanalso found a dose-dependent decrease in PONV rates following administration of Dexamethasone²¹.

Steward et al^{22} did a meta-analysis of randomiseddouble blind placebo controlled trials of a single dose of intravenous intraoperative steroid for paediatric pat entswho underwent tonsillectomy or adenotonsillectomy. Eight trials met their inclusion criteria. They concluded that routine use of steroids would prevent vomiting in one out of four children. In addition, would result in earlier soft or solid diet intake.

Our main aim was to find out the effect of steroidon pain following tonsillectomy. We selected dexamethasone as it is highly potent and has long half-life (36-72 hours) for glucocorticoid activity, so that the effect would remain even after the discharge of the patient. Single IV dose was used, as it is devoid of side effects like gastritis, adrenalsuppression etc.²³ IV drug was given before surgery toachieve peak effect in the early postoperative period.

5. Conclusion

We conclude that, a single IV dose of 0.15 mg/kg dexamethasone, given following induction of anaesthesia, provided good and prolonged antiemeticeffect and resulted in earlier and better quality of oral intake without side effects.

References

- [1] Steward DL, Welge JA, Myer CM. Steroids for improving recovery following tonsillectomy in children. Cochrane Database Syst Rev.2003(1):CD003997.
- [2] Bolton CM, Myles PS, Nolan T, Sterne JA. Prophylaxis of postoperative vomiting in children undergoing tonsillectomy: a systematic review and meta-analysis. Br J Anaesth.2006;97(5):593-604.
- [3] Afman CE, Welge JA, Steward DL. Steroids for posttonsillectomy pain reduction: meta-analysis of randomized controlled trials. Otolaryngol Head Neck Surg.2006;134(2):181-6.
- [4] Steward DL, Welge JA, Myer CM. Do steroids reduce morbidity of tonsillectomy? Meta-analysis of randomized trials. Laryngoscope.2001;111(10):1712-8.
- [5] Goldman AC, Govindaraj S, Rosenfeld RM. A metaanalysis of DXmethasone use with tonsillectomy. Otolaryngol Head Neck Surg.2000;123(6):682-6.
- [6] Hilton M. Tonsillectomy technique—tradition versustechnology. Lancet. 2004;364(9435):642-643.
- [7] Marret E, Flahault A, Samama CM, Bonnet F. Effectsof postoperative, nonsteroidal anti-inflammatorydrugs on bleeding risk after tonsillectomy: metaanalysisof randomized controlled trials. Anesthesiology.2003;98(6):1497-1502.
- [8] Moiniche S, Rømsing J, Dahl JB, Tramèr MR. Nonsteroidalanti-inflammatory drugs and the risk of operativesite bleeding after tonsillectomy: a quantitativesystematic review. AnesthAnalg. 2003;96(1):68-77.
- [9] Henzi I, Walder B, Tramèr MR. Dexamethasone forthe prevention of postoperative nausea and vomiting:a quantitative systematic review. AnesthAnalg.2000;90(1):186-194.
- [10] Gan TJ, Meyer TA, Apfel CC, et al; Society for AmbulatoryAnesthesia. Society for Ambulatory Anesthesiaguidelines for the management of postoperativenausea and vomiting. AnesthAnalg. 2007;105(6):1615-1628.
- [11] Bolton CM, Myles PS, Nolan T, Sterne JA. Prophylaxisof postoperative vomiting in children undergoingtonsillectomy: a systematic review andmetaanalysis. Br J Anaesth. 2006;97(5):593-604.
- [12] Afman CE, Welge JA, Steward DL. Steroids for posttonsillectomypain reduction: meta-analysis of randomizedcontrolled trials. Otolaryngol Head Neck Surg.2006;134(2):181-186.
- [13] Steward DL, Welge JA, Myer CM. Do steroids reducemorbidity of tonsillectomy? meta-analysis of randomizedtrials. Laryngoscope. 2001;111(10):1712-1718.
- [14] Kehlet H. Glucocorticoids for peri-operative analgesia: how far are we from general recommendations? ActaAnaesthesiol Scand. 2007;51(9):1133-1135.

- [15] Kim MS, Cote CJ, Cristoloveanu C, et al. There isno dose-escalation response to dexamethasone(0.0625-1.0 mg/kg) in pediatric tonsillectomy or adenotonsillectomy patients for preventing vomiting, reducingpain, shortening time to first liquid intake, orthe incidence of voice change. AnesthAnalg. 2007;104(5):1052-1058.
- [16] April MM, Callan ND, Nowak DM, Hausdorff MA.The effect of intravenous dexamethasone in pediatricadenotonsillectomy. Arch Otolaryngol Head NeckSurg. 1996;122(2):117-120.
- [17] Tom LW, Templeton JJ, Thompson ME, MarshRR. Dexamethasone in adenotonsillectomy.Int J PediatrOtorhinolaryngol. 1996;37(2):115-120.
- [18] Pappas AL, Sukhani R, Hotaling AJ, et al. The effectof preoperative dexamethasone on the immediate anddelayed postoperative morbidity in children undergoingadenotonsillectomy. AnesthAnalg. 1998;87(1):57-61.
- [19] Hanasono MM, Lalakea ML, Mikulec AA, ShepardKG, Wellis V, Messner AH. Perioperative steroids intonsillectomy using electrocautery and sharp dissectiontechniques. Arch Otolaryngol Head Neck Surg.2004;130(8):917-921.
- [20] Association of PaediatricAnaesthetists of GreatBritain and Ireland. Guidelines on the Prevention ofPostoperative Vomiting in Children. Spring2008.http://www.apagbi.org.uk/docs/APA%20_ Draft_POV_guidelines_%20Jan08.pdf. Accessed August10, 2008.
- [21] Karaman M, Ilhan AE, Dereci G, Tek A. Determination of optimum dosage of intraoperative single dose DXmethasone in pediatric tonsillectomy and adenotonsillectomy. Int J PediatrOtorhinolaryngol. 2009;73(11):1513-5.
- [22] Steward DL, Welge JA, Myer CM. Do steroids reducemorbidity of tonsillectomy? Meta-analysis of randomizedtrials. Laryngoscope 2001; 111(10): 1712-8.
- [23] Melby JC. Drug Spotlight Program: Systemic corticosteroidtherapy – pharmacology and endocrinologic considerations. Ann Intern Med 1974; 81: 505-12.

Volume 8 Issue 4, April 2019 www.ijsr.net

Licensed Under Creative Commons Attribution CC BY